×

ADRO – aduro biotech (US:NASDAQ)

DELAYED
$ usd
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
1D
5D
1M
3M
YTD
1Y
3Y
1 Day ADRO SPY QQQ SPX
Date Time Symbol Headline Impact
8/9 08:00 am adro Aduro Biotech Bolsters Intellectual Property Position in STING Field with Two New Patents Low
8/8 03:01 am adro Aduro Biotech, Inc. (NASDAQ: ADRO) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. Low
8/3 04:05 pm adro Aduro Biotech to Present at the 37th Annual Canaccord Genuity Growth Conference Low
8/3 08:00 am adro Aduro Biotech, Inc. (NASDAQ: ADRO) was given a new $18.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. Medium
8/2 12:57 pm adro Aduro Biotech, Inc. (NASDAQ: ADRO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. Low
7/27 08:00 am adro Aduro Biotech Announces Andrea van Elsas, Ph.D., to be Named Chief Scientific Officer Effective September 1, 2017 Medium
7/18 07:27 am adro Aduro Biotech, Inc. (NASDAQ: ADRO) is now covered by analysts at Cowen and Company. They set an "outperform" rating on the stock. Low
7/13 08:00 am adro Aduro Announces Milestone Achieved Relating to Collaboration with Merck for Development of Anti-CD27 Antibody for the Treatment of Cancer Neutral
7/4 12:31 pm adro Aduro Biotech, Inc. (NASDAQ: ADRO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $13.00 price target on the stock. Medium
6/29 04:05 pm adro Aduro Biotech Announces Initiation of Phase 2 Clinical Trial of CRS-207 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Previously-Treated Gastroesophageal Adenocarcinoma Low
6/28 04:05 pm adro Aduro Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of CRS-207 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Previously Treated Malignant Pleural Mesothelioma Low
6/1 08:05 am adro Aduro Biotech Announces FDA Clearance of Investigational New Drug Application to Evaluate the Combination of ADU-S100 with PDR001 for the Treatment of Solid Tumors and Lymphomas Medium
5/26 07:05 am adro Aduro Biotech to Host and Webcast an Investor Event in Conjunction with the 2017 ASCO Annual Meeting Low
5/23 01:10 pm adro Aduro BioTech (ADRO) Presents At Bank of America Merrill Lynch 2017 Health Care Conference - Slideshow [Seeking Alpha] Low
5/17 09:05 am adro Aduro Biotech Announces Clinical Collaboration with Merck to Evaluate the Combination of Aduro’s CRS-207 with Merck’s KEYTRUDA® (Pembrolizumab) for the Treatment of Mesothelioma Medium
5/2 04:05 pm adro Aduro Biotech Reports First Quarter 2017 Financial Results Medium
5/2 11:15 am adro Aduro BioTech Inc (NASDAQ: ADRO) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong sell" rating. Low
5/1 07:24 am adro Aduro BioTech Inc (NASDAQ: ADRO) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $18.00 price target on the stock. Low
4/25 08:00 am adro Aduro Biotech to Present at Two Investor Conferences in May Medium
4/20 04:05 pm adro Aduro Biotech Announces Management Promotions Medium
3/28 03:04 pm adro Aduro BioTech Inc (NASDAQ: ADRO) was given a new $30.00 price target on by analysts at Canaccord Genuity. They now have a "buy" rating on the stock. Low
3/15 09:00 am adro Aduro Biotech to Host Research and Development Day in New York Low
3/14 02:15 pm adro Aduro BioTech (ADRO) Presents At 29th Annual ROTH Conference [Seeking Alpha] Low
3/13 09:15 am adro Is A Runup For Aduro Biotech In The Cards For 2017? [Seeking Alpha] Low
3/10 09:00 am adro Aduro Biotech Awarded East Bay Innovation Award for its Contributions in Life Sciences and the San Francisco East Bay Community Medium
3/7 09:04 pm adro Aduro BioTech Inc (NASDAQ: ADRO) had its "buy" rating re-affirmed by analysts at FBR & Co. They now have a $23.00 price target on the stock. Medium
3/6 04:05 pm adro Aduro Biotech Announces Upcoming Data Presentations at the 2017 American Association for Cancer Research Annual Meeting Medium
3/2 04:05 pm adro Aduro Biotech Announces Upcoming Data Presentations at the Keystone Symposia on Cancer Immunology and Immunotherapy Conference Neutral
3/1 04:05 pm adro Aduro Biotech Announces Fourth Quarter and Full Year 2016 Financial Results Low
2/28 08:00 am adro Aduro Biotech to Present at Two Investor Conferences in March Medium
2/10 08:00 am adro Aduro Biotech to Present at the Leerink Partners 6th Annual Global Healthcare Conference Low
1/26 08:00 am adro Aduro Biotech Announces Appointment of Leading Immunotherapy and Oncology Experts to Scientific Advisory Board Low
1/24 10:54 am adro BRIEF-Aduro acquires Chrysallis to expand human performance offering [Reuters] Low
1/19 03:02 pm adro Aduro Biotech Inc. (NASDAQ: ADRO) was given a new $30.00 price target on by analysts at Canaccord Genuity. They now have a "buy" rating on the stock. Low
1/9 08:00 am adro Aduro Biotech Announces Clinical Collaboration with Merck to Evaluate the Combination of Aduro’s CRS-207 with Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Gastric Cancer Low
12/27 04:00 pm adro Aduro Biotech to Present at the 35th Annual J.P. Morgan Healthcare Conference Low
12/7 03:26 pm adro Aduro Biotech Inc. (NASDAQ: ADRO) was given a new $30.00 price target on by analysts at Canaccord Genuity. They now have a "buy" rating on the stock. Low
12/6 05:00 am adro Aduro Biotech Europe’s Hans van Eenennaam, Ph.D. and John Dulos, Ph.D. Honored with the Intellectual Property Owners Education Foundation’s 43rd Inventor of the Year Award for Contributions in the Discovery of KEYTRUDA® (pembrolizumab) Medium
12/5 12:40 pm adro Merck unit picks up CD27 antibody developed by Aduro Biotech [Seeking Alpha] Low
11/26 08:29 am adro Aduro Biotech Inc. (NASDAQ: ADRO) had its "buy" rating re-affirmed by analysts at Roth Capital. They now have a $20.00 price target on the stock. Medium
11/23 01:48 am adro Aduro Biotech Inc. (NASDAQ: ADRO) had its "buy" rating re-affirmed by analysts at FBR & Co. Low
11/21 12:39 pm adro Aduro Biotech Inc. (NASDAQ: ADRO) was given a new $30.00 price target on by analysts at Canaccord Genuity. They now have a "buy" rating on the stock. Low
11/14 07:58 pm adro Aduro Biotech Inc. (NASDAQ: ADRO) had its "outperform" rating re-affirmed by analysts at FBR & Co. They now have a $20.00 price target on the stock. Medium
11/12 08:00 am adro Aduro Biotech Highlights Positive Clinical Results from Second Cohort of Phase 1b Mesothelioma Clinical Trial Low
11/9 04:00 pm adro Aduro Biotech’s Personalized LADD Therapy Featured in an Oral Presentation at SITC’s New Cancer Immunotherapy Agents in Development Program Low
11/7 08:00 am adro Aduro Biotech Presents Preclinical Data Demonstrating Acute and Systemic Immune Activation through STING Pathway Stimulation with ADU-S100 Medium
11/2 04:00 pm adro Aduro Biotech Reports Third Quarter 2016 Financial Results Medium
10/27 09:40 am adro Aduro Biotech Inc. (NASDAQ: ADRO) had its "buy" rating re-affirmed by analysts at Roth Capital. They now have a $20.00 price target on the stock, down previously from $22.00. Medium
10/26 11:50 am adro Aduro Biotech Inc. (NASDAQ: ADRO) had its "outperform" rating re-affirmed by analysts at FBR & Co. They now have a $20.00 price target on the stock, down previously from $22.00. Low
10/24 08:00 am adro Aduro Biotech Reports Partial Clinical Hold to Pause Enrollment in LADD Trials Low
Date Time Symbol Company Name Action %Chg
8/2 04:01 pm ADRO aduro biotech BEAT -5.6%
5/2 04:05 pm ADRO aduro biotech BEAT 4.1%
3/1 04:05 pm ADRO aduro biotech MISS 0.0%
11/2 04:00 pm ADRO aduro biotech MISS -7.9%
Date Time Action From To Firm Impact %CHG DETAILS
8/8 03:01 am Downgrades Hold Sell BidaskClub Low 0.4%
8/2 12:57 pm Downgrades Buy Hold Zacks Investment Research Low -0.4%
7/18 06:51 am Initiates OUTPERFORM COWEN Low 0.8%
7/4 12:31 pm Upgrades Hold Buy Zacks Investment Research Medium 3.6%
5/3 01:07 pm Reiterates Buy Canaccord Genuity Low -1.0%
5/2 11:15 am Downgrades Hold Strong Sell Zacks Investment Research Low 1.3%
5/1 07:05 am Initiates BUY RODMAN & RENSHAW Low 0.5%
3/7 08:54 am Reinstates Buy Roth Capital Medium -3.2%
11/26 08:29 am Reiterates Buy Roth Capital Medium -9.7%
11/23 01:48 am Reiterates Buy FBR & Co Low 1.1%
11/14 07:58 pm Reiterates Outperform FBR & Co Medium -6.0%
10/27 09:40 am Reiterates Buy Roth Capital Medium -7.4%
10/26 11:50 am Reiterates Outperform FBR & Co Low -1.2%
10/24 10:57 am Reiterates Outperform Leerink Swann Medium 3.3%
Date Time Symbol Headline Impact
8/16 06:01 am adro Form EFFECT ADURO BIOTECH, INC. Low
8/14 06:01 am adro Form EFFECT ADURO BIOTECH, INC. Low
8/9 07:42 pm adro Form 4 ADURO BIOTECH, INC. For: Aug 07 Medium
8/2 04:29 pm adro Form S-3 ADURO BIOTECH, INC. Medium
7/24 08:01 am adro Form 10-K/A ADURO BIOTECH, INC. For: Dec 31 Low
7/6 07:11 pm adro Form 4 ADURO BIOTECH, INC. For: Jul 03 Filed by: Dubensky Thomas W. Medium
6/30 06:01 pm adro Form 4 ADURO BIOTECH, INC. For: Jun 28 Filed by: SCHAFER GREGORY W Medium
6/21 06:56 pm adro Form 4 ADURO BIOTECH, INC. For: Jun 19 Filed by: ISAACS STEPHEN T Low
6/14 09:04 pm adro Form 4 ADURO BIOTECH, INC. For: Jun 12 Filed by: Brockstedt Dirk G. Low
6/12 05:02 pm adro Form 8-K ADURO BIOTECH, INC. For: Jun 08 Low
6/5 07:23 pm adro Form 4 ADURO BIOTECH, INC. For: Jun 01 Filed by: Brockstedt Dirk G. Low
5/18 08:30 pm adro Form 4 ADURO BIOTECH, INC. For: May 17 Filed by: Templeman Blaine Low
5/17 05:56 pm adro Form 4 ADURO BIOTECH, INC. For: May 15 Filed by: ISAACS STEPHEN T Low
5/15 06:56 pm adro Form 4 ADURO BIOTECH, INC. For: May 11 Filed by: Dubensky Thomas W. Low
5/2 04:27 pm adro Form 10-Q ADURO BIOTECH, INC. For: Mar 31 Medium
4/21 05:14 pm adro Form DEF 14A ADURO BIOTECH, INC. For: Jun 08 Medium
4/4 08:18 pm adro Form 4 ADURO BIOTECH, INC. For: Apr 03 Filed by: ISAACS STEPHEN T Low
3/14 08:03 pm adro Form 4 ADURO BIOTECH, INC. For: Mar 13 Filed by: ISAACS STEPHEN T Low
3/10 08:05 pm adro Form 4 ADURO BIOTECH, INC. For: Mar 09 Filed by: Dubensky Thomas W. Low
3/6 11:34 am adro Form CT ORDER ADURO BIOTECH, INC. Low
3/1 04:32 pm adro Form 8-K ADURO BIOTECH, INC. For: Mar 01 Low
2/14 10:43 am adro Form SC 13G/A ADURO BIOTECH, INC. Filed by: FMR LLC Medium
2/9 09:54 am adro Form SC 13G/A ADURO BIOTECH, INC. Filed by: WELLINGTON MANAGEMENT GROUP LLP Low
1/19 06:52 pm adro Form 4 ADURO BIOTECH, INC. For: Jan 17 Filed by: Brockstedt Dirk G. Low
1/13 04:34 pm adro Form 4 ADURO BIOTECH, INC. For: Jan 11 Filed by: Templeman Blaine Medium
1/10 04:13 pm adro Form SC 13G ADURO BIOTECH, INC. Filed by: SINGER JAMES R Low
1/9 09:03 am adro Form 8-K ADURO BIOTECH, INC. For: Jan 09 Low
1/5 05:15 pm adro Form 4 ADURO BIOTECH, INC. For: Jan 03 Filed by: ISAACS STEPHEN T Low
12/27 09:12 am adro Form 4 ADURO BIOTECH, INC. For: Dec 23 Filed by: SCHAFER GREGORY W Low
12/16 07:10 pm adro Form 4 ADURO BIOTECH, INC. For: Dec 15 Filed by: ISAACS STEPHEN T Medium
12/15 04:29 pm adro Form 8-K ADURO BIOTECH, INC. For: Dec 09 Low
12/14 09:04 pm adro Form 4 ADURO BIOTECH, INC. For: Dec 12 Filed by: Brockstedt Dirk G. Low
12/5 07:21 pm adro Form 4 ADURO BIOTECH, INC. For: Dec 01 Filed by: Dubensky Thomas W. Medium
11/21 08:06 am adro Form 8-K ADURO BIOTECH, INC. For: Nov 21 Low
11/16 05:06 pm adro Form 4 ADURO BIOTECH, INC. For: Nov 14 Filed by: ISAACS STEPHEN T Low
11/14 07:00 pm adro Form 4 ADURO BIOTECH, INC. For: Nov 10 Filed by: Dubensky Thomas W. Medium
11/10 11:56 am adro Form SC 13G ADURO BIOTECH, INC. Filed by: WELLINGTON MANAGEMENT GROUP LLP Low
11/2 04:08 pm adro Form 10-Q ADURO BIOTECH, INC. For: Sep 30 Medium
10/24 04:35 pm adro Form 8-K ADURO BIOTECH, INC. For: Oct 24 Low
10/5 05:18 pm adro Form 4 ADURO BIOTECH, INC. For: Oct 03 Filed by: Dubensky Thomas W. Medium
9/21 04:58 pm adro Form 4 ADURO BIOTECH, INC. For: Sep 19 Filed by: Lew Jennifer Low
9/14 04:20 pm adro Form 4 ADURO BIOTECH, INC. For: Sep 12 Filed by: SCHAFER GREGORY W Medium
9/12 05:39 pm adro Form 3 ADURO BIOTECH, INC. For: Aug 31 Filed by: Sacks Natalie Medium
9/2 04:25 pm adro Form 4 ADURO BIOTECH, INC. For: Sep 01 Filed by: Dubensky Thomas W. Medium
Stock Stats
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny

Odd Lot

Avg. bid-ask spread

Avg. bid / ask size


Shares at ask / bid


Off exchange

Don’t Miss Out On The Next BIG Stock Move

Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.